Neelim Healthcare Consulting
Neelim

Gastroenterology Prometric exam questions

Exam-length papers covering every published domain for Gastroenterology.

Tell us which regulator you are sitting and we send the bank prepared for that authority's exam.

For DHA · MOHAP · SHA · SCFHS · QCHP · NHRADHA GES5171Pass mark DHA 65% · SCFHS 65% · QCHP 65%From 3 papers · ~170 Qs each
AED 319one-time
About a third of one exam fee
Request this question bank

Tell us your authority and we send the bank for that exam, usually the same day.

Or sit 25 questions free first →

What is riding on this exam

~AED 1,030
DHA exam fee, per attempt
Paid again on every re-sit. Other regulators' fees are in the table below.
3
UAE attempts - in total
Shared across DHA, DOH, MOHAP and SHA, not three each. Saudi, Qatar, Oman and Kuwait rules are in the FAQ.
65%
Pass mark, by regulator
DHA 65%, SCFHS 65%, QCHP 65%. Other regulators in the table below.

One failed attempt costs you the fee again, plus months of delay on your licence, your visa and your start date. This bank costs about a third of one exam fee.

Every regulator: format, pass marks and fees for all GCC licensing exams, each from the regulator's own documents.

The Gastroenterology exam at a glance

DHA (UAE) publishes a Gastroenterology exam of 150 MCQs in 3 hours with a 65% pass mark; SCFHS (Saudi Arabia) publishes a Gastroenterology exam of 200 MCQs in 240 minutes with a 65% pass mark; QCHP (Qatar) publishes a Gastroenterology exam of 150 MCQs in 3 hours with a 65% pass mark. MOHAP, SHA, NHRA do not publish Gastroenterology-specific figures; their regulator-wide format and pass-mark rules are in the full table. DOH licenses the title without a published written exam (credential review, interview or an unpublished assessment). OMSB, Kuwait MOH publish no exam for this title.

DHA · UAE
Specialist Gastroenterology (GES5171)
150 MCQs in 3 hours · pass mark 65% · USD 280 (about AED 1,030) · checked September 2026
SCFHS · Saudi Arabia
Saudi Classification Examination - Gastroenterology
200 MCQs in 240 minutes · pass mark 65% · checked October 2026
QCHP · Qatar
Specialist Gastroenterology
150 MCQs in 3 hours · pass mark 65% · checked September 2026

From each regulator's own exam documents; the DHA row is from the DHA CBT Guideline, Sep 2026. Every other regulator is in the full GCC table.

Try two questions from this bank

Original questions from the bank - pick an answer to see the rationale and reference.

Q1Patient Safety, Professionalism, Ethics and Evidence-Based Practice

During a screening colonoscopy a caecal perforation occurs and is closed with clips; the patient is admitted for observation and recovers well. The endoscopist's approach to the patient afterwards should be to:

Choose an answer to see the rationale.

Q2Viral Hepatitis, Acute Liver Injury and Transplantation

A patient develops liver injury 5 weeks after starting a new drug. ALT is 8 times the upper limit of normal and ALP is 1.2 times the upper limit of normal. Which pattern does this represent and what is the corresponding R value?

Choose an answer to see the rationale.

Not sure where you stand? Sit 25 of these questions free, timed at real exam pace, and see which domains you are weakest in.

Take the free mock exam →

Liked those? The full bank has 510 questions at this standard - every one with a rationale and a reference.

Get the full bank - AED 319

What's inside

  • ✓3 to 6 full-length papers (~170 Q each)
  • ✓No question repeated between papers
  • ✓Four options, one unambiguous best answer
  • ✓A full rationale on every question
  • ✓A real guideline or textbook reference
  • ✓Every sub-topic in the published blueprint
  • ✓Researched by Neelim's exam research team
  • ✓Prepared for your authority's exam, not a generic set

The Gastroenterology exam in every GCC country

Gastroenterology licensing exam in every GCC country
RegulatorExamFormatPass markFee per attempt
Specialist Gastroenterology (GES5171)
150 MCQs in 3 hours65%USD 280 (about AED 1,030)
SCFHS
Kingdom of Saudi Arabia
Practise →
Saudi Classification Examination - Gastroenterology
200 MCQs in 240 minutes65%Not published
QCHP
State of Qatar
Practise →
Specialist Gastroenterology
150 MCQs in 3 hours65%Not published
DOH
Abu Dhabi, Al Ain and Al Dhafra
Practise →
No written exam published
Oral assessment, 45-60 minutes; no written exam (DOH Licensing Procedure Manual 2024)
Panel / reviewNot publishedNot published
MOHAP
Northern Emirates - Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah
Practise →
MOHAP licensing exam
Regulator-wide format
Computer-basedNot publishedNot published
SHA
Emirate of Sharjah
Practise →
SHA licensing exam
Regulator-wide format
Set at assessmentNot publishedNot published
NHRA
Kingdom of Bahrain
Practise →
NHRA licensing exam
Regulator-wide format
Prometric CBTNot publishedNot published
OMSB
Sultanate of Oman
Practise →
No exam published for this title
No OMSB exam published for this title; check with OMSB
Not publishedNot publishedNot published
Kuwait MOH
State of Kuwait
Practise →
No exam published for this title
Kuwait MOH publishes no exam for this title; check with the MOH
Not publishedNot publishedNot published

Highlighted rows publish figures for this exact Gastroenterology exam; the others show the regulator's general rules.

From each regulator's own exam pages; anything a regulator does not publish says so. Assessment mode also depends on your licence title, so confirm your route on your eligibility notice.

Try 15 free Gastroenterology questions with answersDifferent from the samples on this page - each with a full explanationStart →

What the Gastroenterology exam covers

The published blueprint for this exam breaks into 13 domains and 255 testable sub-topics. Our bank covers every one of them - here is the full map, so you can see exactly what you are expected to know.

Oesophageal Diseases~8% (part of the SCFHS/DHA published section 'Oesophageal and Gastric Diseases' at 14%; split here for granularity - est.)19 topics
  • GERD: pathophysiology, Montreal definition, extra-oesophageal and atypical presentations
  • PPI therapy: dosing, on-demand vs maintenance, PPI-refractory reflux, long-term safety concerns
  • Ambulatory pH and pH-impedance monitoring: on vs off therapy, DeMeester score, symptom association probability
  • High-resolution manometry and the Chicago Classification v4.0
  • Achalasia subtypes I-III: diagnosis, timed barium oesophagram, pneumatic dilatation vs Heller myotomy vs POEM
  • Other motility disorders: distal oesophageal spasm, hypercontractile (jackhammer) oesophagus, absent contractility, EGJ outflow obstruction
  • +13 more in the bank
Gastric and Duodenal Diseases and Helicobacter pylori~6% (remainder of the SCFHS/DHA 'Oesophageal and Gastric Diseases' 14% section - est. split)19 topics
  • Peptic ulcer disease: pathogenesis, H. pylori vs NSAID vs idiopathic ulcers
  • Helicobacter pylori: invasive and non-invasive testing, effect of PPI/antibiotics on test accuracy
  • H. pylori eradication regimens: bismuth quadruple, concomitant, levofloxacin salvage, clarithromycin resistance and regional resistance patterns
  • Confirmation of eradication and management of repeated treatment failure, culture and susceptibility testing
  • NSAID and aspirin gastropathy: risk stratification, co-therapy, COX-2 selectivity, resumption after bleeding
  • Refractory and recurrent ulcers: gastrinoma, Crohn's, malignancy, non-adherence
  • +13 more in the bank
Gastrointestinal Bleeding~15% (SCFHS/DHA published section: 15%)20 topics
  • Initial resuscitation in acute GI bleed: airway, fluids, restrictive vs liberal transfusion thresholds (Hb 7 g/dL)
  • Risk scores: Glasgow-Blatchford, Rockall, AIMS65, Oakland score for lower GI bleeding, and outpatient management criteria
  • Pre-endoscopic pharmacotherapy: PPI infusion vs high-dose oral, prokinetics, tranexamic acid evidence (HALT-IT)
  • Timing of upper endoscopy (within 24 hours) and evidence against very early (<12 h) endoscopy in high-risk patients
  • Forrest classification of peptic ulcer stigmata and rebleeding risk by class
  • Endoscopic haemostasis techniques: injection, thermal contact, argon plasma coagulation, through-the-scope and over-the-scope clips, haemostatic powders/gels
  • +14 more in the bank
Pancreatic Diseases~8% (part of the SCFHS/DHA published section 'Pancreaticobiliary Diseases' at 15%; split here for granularity - est.)20 topics
  • Acute pancreatitis: revised Atlanta classification, diagnostic triad, aetiological work-up including idiopathic cases
  • Severity prediction: BISAP, APACHE II, persistent organ failure; early aggressive vs moderate fluid resuscitation (WATERFALL)
  • Early management: goal-directed lactated Ringer's, early enteral feeding, analgesia, role and non-role of antibiotics
  • Gallstone pancreatitis: timing of ERCP (only for cholangitis/obstruction) and index-admission cholecystectomy
  • Local complications: acute peripancreatic fluid collection, pseudocyst, acute necrotic collection, walled-off necrosis
  • Infected necrosis: diagnosis, step-up approach, percutaneous vs EUS-guided drainage with lumen-apposing metal stents, endoscopic necrosectomy
  • +14 more in the bank
Biliary Tract and Gallbladder Disease~7% (remainder of the SCFHS/DHA 'Pancreaticobiliary Diseases' 15% section - est. split)19 topics
  • Gallstone disease: risk factors, biliary colic, natural history of asymptomatic stones
  • Acute cholecystitis: Tokyo Guidelines grading, cholecystectomy timing, percutaneous vs EUS-guided gallbladder drainage
  • Choledocholithiasis: ASGE/ESGE probability stratification, MRCP vs EUS vs ERCP selection
  • Acute cholangitis: Charcot/Reynolds, Tokyo Guidelines severity, timing of urgent biliary decompression, antibiotics
  • ERCP technique and accessories: cannulation strategies, sphincterotomy, sphincteroplasty (large balloon dilation), mechanical/cholangioscopic lithotripsy
  • Difficult stones and altered anatomy: Roux-en-Y and Billroth II, balloon enteroscopy-assisted ERCP, EUS-directed transgastric ERCP (EDGE)
  • +13 more in the bank
Chronic Liver Disease, Cirrhosis and Portal Hypertension~13% (part of the SCFHS/DHA published section 'Liver and Liver Related Conditions and Diseases' at 25%; split here for granularity - est.)20 topics
  • Non-invasive fibrosis assessment: FIB-4, NFS, transient elastography (FibroScan), ELF, MR elastography and their cut-offs
  • Compensated advanced chronic liver disease and the Baveno VII criteria, clinically significant portal hypertension and HVPG >=10 mmHg
  • MASLD/MASH (formerly NAFLD/NASH): nomenclature, metabolic criteria, natural history, resmetirom and GLP-1 based therapy, weight loss targets
  • Alcohol-related liver disease: quantification, alcohol-associated hepatitis, Maddrey DF, MELD, Lille score, corticosteroid use, abstinence and relapse prevention
  • Ascites: SAAG interpretation, diagnostic paracentesis, sodium restriction, diuretic regimens, refractory ascites, large-volume paracentesis with albumin
  • Spontaneous bacterial peritonitis: diagnosis (PMN >=250), treatment, albumin indications, primary and secondary prophylaxis, resistance patterns
  • +14 more in the bank
Viral Hepatitis, Acute Liver Injury and Transplantation~10% (remainder of the SCFHS/DHA 'Liver and Liver Related Conditions and Diseases' 25% section - est. split)20 topics
  • Hepatitis A and E: epidemiology, HEV genotypes, chronic HEV in immunosuppression, pregnancy risk, vaccination
  • Hepatitis B serology interpretation: HBsAg, anti-HBs, anti-HBc IgM/IgG, HBeAg/anti-HBe, HBV DNA, occult HBV
  • Chronic hepatitis B phases: HBeAg-positive/negative infection vs hepatitis, indications to treat, tenofovir vs entecavir, TAF vs TDF
  • HBV reactivation risk with immunosuppression, rituximab, chemotherapy and biologics; prophylaxis strategy
  • HBV in pregnancy: antiviral prophylaxis in the third trimester, immunoglobulin plus vaccine for the neonate
  • Hepatitis D: screening, prognosis, bulevirtide and interferon
  • +14 more in the bank
Inflammatory Bowel Disease~4% (part of the SCFHS/DHA published section 'Inflammatory Bowel Diseases, Small and Large Intestine' at 6%; SCFHS Fellowship promotion blueprint weights IBD at 25% - est. split for the licensure paper)20 topics
  • Epidemiology, genetics (NOD2/CARD15) and environmental risk factors; distinguishing UC from Crohn's disease
  • Diagnostic work-up: ileocolonoscopy with segmental biopsies, faecal calprotectin, CT/MR enterography, intestinal ultrasound
  • Disease classification: Montreal classification, Mayo endoscopic subscore, SES-CD, UCEIS
  • Ulcerative colitis medical management: 5-ASA optimisation, topical therapy, steroids, thiopurines
  • Crohn's disease medical management by phenotype: inflammatory, stricturing, penetrating; exclusive enteral nutrition
  • Anti-TNF therapy: infliximab, adalimumab, certolizumab - loss of response, immunogenicity, combination therapy
  • +14 more in the bank
Small and Large Intestine Disorders (non-IBD)~3% (remainder of the SCFHS/DHA 'Inflammatory Bowel Diseases, Small and Large Intestine' 6% section - est. split)20 topics
  • Coeliac disease: serology (tTG-IgA with total IgA), Marsh classification, HLA-DQ2/DQ8, gluten challenge, non-responsive and refractory coeliac disease
  • Non-coeliac gluten sensitivity and wheat allergy
  • Small intestinal bacterial overgrowth: breath testing limitations, aspirate culture, antibiotic cycling
  • Chronic diarrhoea: osmotic vs secretory vs inflammatory vs fatty; stool osmotic gap, faecal fat, faecal elastase
  • Bile acid diarrhoea: SeHCAT, 7alpha-C4, sequestrant therapy
  • Microscopic colitis: lymphocytic vs collagenous, drug associations, budesonide
  • +14 more in the bank
Gastrointestinal and Hepatobiliary Malignancies~9% (SCFHS/DHA published section 'Gastrointestinal Malignancies': 9%)20 topics
  • Oesophageal adenocarcinoma and squamous cell carcinoma: risk factors, staging with EUS/PET-CT, endoscopic vs surgical vs multimodal therapy
  • Gastric adenocarcinoma: Lauren classification, H. pylori attribution, early gastric cancer and endoscopic resection criteria
  • Hereditary diffuse gastric cancer (CDH1) and prophylactic gastrectomy
  • Gastric MALT lymphoma: H. pylori eradication as first-line therapy, t(11;18) non-responders, follow-up
  • Gastrointestinal stromal tumours: EUS features, risk stratification, KIT/PDGFRA mutations, imatinib
  • Subepithelial lesions: EUS layer of origin, leiomyoma, lipoma, pancreatic rest, carcinoid; sampling strategies
  • +14 more in the bank
GI Motility, Functional GI Disorders and Nutrition~6% (SCFHS/DHA published section 'Gastroenterology Nutrition Motility Disorders': 6%)19 topics
  • Rome IV framework for disorders of gut-brain interaction and the biopsychosocial model
  • Irritable bowel syndrome subtypes: diagnostic criteria, alarm features, limited testing strategy
  • IBS therapy: low-FODMAP diet, fibre, antispasmodics, rifaximin, eluxadoline, linaclotide, lubiprostone, neuromodulators, gut-directed hypnotherapy and CBT
  • Chronic constipation: normal transit, slow transit, defaecatory disorder; transit studies and anorectal manometry with balloon expulsion
  • Pharmacological therapy for constipation: osmotic and stimulant laxatives, secretagogues, prucalopride, naloxegol for opioid-induced constipation
  • Biofeedback and pelvic floor rehabilitation for dyssynergic defaecation
  • +13 more in the bank
Endoscopy Practice, Sedation and Procedural Complications (Miscellaneous)~4% (est. - the DHA exam coverage list includes a 'Miscellaneous' heading and names Cotton & Williams Practical Gastrointestinal Endoscopy as a core reference; not a separately weighted SCFHS section)19 topics
  • Informed consent for endoscopy: material risks, alternatives, capacity, and documentation standards
  • Pre-procedure risk assessment: ASA grade, airway assessment, anticoagulation and antiplatelet management per ASGE/ESGE/BSG guidance
  • Sedation for endoscopy: midazolam/opioid, propofol, monitored anaesthesia care, capnography, reversal agents and rescue
  • Management of sedation-related adverse events: hypoxaemia, aspiration, hypotension, arrhythmia
  • Bowel preparation regimens, split dosing, preparation in renal impairment and constipation; consequences of inadequate preparation
  • Antibiotic prophylaxis in endoscopy: where it is and is not indicated (cirrhosis with GI bleed, PEG, EUS-FNA of cysts, ERCP with incomplete drainage)
  • +13 more in the bank
Patient Safety, Professionalism, Ethics and Evidence-Based Practice~10% (SCFHS/DHA published: Patient Safety 5% + Professionalism and Ethics 5%; the SCFHS Fellowship blueprint instead embeds these across domains)20 topics
  • Principles of medical ethics: autonomy, beneficence, non-maleficence, justice, applied to endoscopic and hepatology decisions
  • Informed consent, assent, capacity assessment and surrogate decision-making
  • Truth-telling, breaking bad news (SPIKES) and family-mediated disclosure norms in Gulf practice
  • Confidentiality, data protection, and the limits of disclosure to family and employers
  • Disclosure of medical error and open disclosure after a procedural complication
  • Do-not-resuscitate decisions, futility, palliative care and end-of-life care in end-stage liver disease
  • +14 more in the bank

12 worked Gastroenterology practice questions

Original exam-style questions from the bank, spread across the blueprint domains. They are not real or recalled exam questions. Try each one, then open the answer for the rationale and reference. None of them appear in the free mock exam, so reading them will not spoil it.

  1. Question 1 · Gastrointestinal Bleeding

    A 58-year-old man with cirrhosis has had two episodes of bleeding from isolated fundal varices (IGV1) despite cyanoacrylate injection. Cross-sectional imaging shows a large spontaneous gastrorenal shunt, and he has recurrent hepatic encephalopathy with well-preserved synthetic function. Which intervention is most appropriate?

    1. ARepeat oesophageal band ligation programme
    2. BLong-term octreotide infusion via an ambulatory pump
    3. CTransjugular intrahepatic portosystemic shunt
    4. DBalloon-occluded retrograde transvenous obliteration (BRTO)
    Show answer and explanation

    Correct answer: D. Balloon-occluded retrograde transvenous obliteration (BRTO)

    BRTO occludes the gastrorenal shunt that feeds the fundal varices and is highly effective for refractory gastric variceal bleeding; unlike TIPS it does not divert portal flow away from the liver and therefore does not aggravate hepatic encephalopathy, which makes it particularly suitable here. TIPS would be expected to worsen his encephalopathy. Band ligation addresses oesophageal rather than fundal varices, and chronic octreotide infusion is not an accepted long-term strategy.

    Reference: AASLD Practice Guidance on Portal Hypertensive Bleeding in Cirrhosis, 2021; Baveno VII, J Hepatol 2022

  2. Question 2 · Viral Hepatitis, Acute Liver Injury and Transplantation

    A 45-year-old sheep farmer has an 8 cm unilocular hepatic cyst with a detached inner membrane (WHO CE3a) and positive Echinococcus serology. There is no biliary communication on MRCP. Which management approach is most appropriate?

    1. APAIR (puncture, aspiration, injection of a scolicidal agent, re-aspiration) under albendazole cover started before and continued after the procedure
    2. BSimple percutaneous aspiration without any scolicidal agent or antiparasitic cover
    3. CObservation alone with repeat ultrasound in 5 years
    4. DERCP with sphincterotomy as first-line therapy
    Show answer and explanation

    Correct answer: A. PAIR (puncture, aspiration, injection of a scolicidal agent, re-aspiration) under albendazole cover started before and continued after the procedure

    Active (CE1) and transitional (CE3a) hydatid cysts of suitable size without biliary communication are appropriately treated by PAIR combined with albendazole started at least 4 hours to several days before the procedure and continued for about a month afterwards, which reduces recurrence and the consequences of spillage. Aspiration without scolicidal agent or drug cover risks secondary echinococcosis and anaphylaxis. Watchful waiting suits only inactive CE4/CE5 cysts, and ERCP is used for cystobiliary fistula or biliary obstruction, not as primary therapy.

    Reference: WHO Informal Working Group on Echinococcosis: Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis (Acta Tropica, 2010)

  3. Question 3 · Gastrointestinal and Hepatobiliary Malignancies

    A 79-year-old woman with multiple comorbidities and an ASA grade IV presents with acute large bowel obstruction from an obstructing sigmoid adenocarcinoma with hepatic metastases. She is haemodynamically stable with no signs of perforation. What is the most appropriate management of her obstruction?

    1. AEmergency Hartmann's procedure
    2. BColonic self-expanding metal stent placement as definitive palliation
    3. CConservative management with nasogastric decompression alone
    4. DLoop ileostomy under general anaesthesia followed by chemotherapy
    Show answer and explanation

    Correct answer: B. Colonic self-expanding metal stent placement as definitive palliation

    In incurable obstructing left-sided colorectal cancer, endoscopic self-expanding metal stent placement is the preferred palliative decompression, offering lower morbidity and mortality and avoiding a stoma compared with emergency surgery, particularly in high-risk patients. Emergency Hartmann's carries high perioperative mortality in an ASA IV patient. Nasogastric decompression alone will not relieve a fixed mechanical obstruction, and a surgical stoma imposes unnecessary operative risk when stenting is feasible.

    Reference: ESGE Guideline: Self-expandable metal stents for obstructing colonic and oesophageal disease (2020/2021 update); WSES/ESCP guidance on obstructing colon cancer

  4. Question 4 · Pancreatic Diseases

    A 57-year-old man with necrotising pancreatitis deteriorates on day 21 with rigors and rising inflammatory markers. CT shows a partially encapsulated retroperitoneal collection containing gas bubbles, extending along the left paracolic gutter, without a mature wall adjacent to the stomach. He is on the intensive care unit on low-dose vasopressors. What is the most appropriate management?

    1. AImmediate open surgical necrosectomy with continuous lavage
    2. BImmediate EUS-guided transgastric lumen-apposing metal stent placement with direct necrosectomy
    3. CAntibiotics alone and repeat CT in one week
    4. DAntibiotics plus percutaneous catheter drainage, escalating only if he fails to improve
    Show answer and explanation

    Correct answer: D. Antibiotics plus percutaneous catheter drainage, escalating only if he fails to improve

    Gas within the collection with clinical sepsis indicates infected necrosis, which requires antibiotics and drainage, but a step-up approach starting with the least invasive option gives the lowest rate of major complications and death. With no mature wall apposed to the stomach and a deep left paracolic extension, percutaneous drainage is the appropriate first step, with escalation to video-assisted retroperitoneal or endoscopic necrosectomy only if the patient fails to improve; roughly a third avoid necrosectomy altogether. Primary open necrosectomy carries high morbidity and mortality, and antibiotics alone rarely control established infected necrosis.

    Reference: van Santvoort HC et al. PANTER step-up trial (N Engl J Med, 2010); van Brunschot S et al. TENSION trial (Lancet, 2018); ACG Clinical Guideline (2024)

  5. Question 5 · Gastric and Duodenal Diseases and Helicobacter pylori

    A 42-year-old woman with multiple duodenal ulcers, diarrhoea and weight loss is suspected of having Zollinger-Ellison syndrome. Her PPI has been withheld for one week. Fasting serum gastrin is 480 pg/mL (normal <100) and gastric pH is 1.8. A secretin stimulation test is performed. Which result best supports the diagnosis?

    1. AA fall in serum gastrin of more than 50% from baseline
    2. BA rise in serum gastrin of more than 120 pg/mL above baseline
    3. CNo change in serum gastrin with a rise in serum chromogranin A
    4. DA rise in serum gastrin only after a protein-rich meal
    Show answer and explanation

    Correct answer: B. A rise in serum gastrin of more than 120 pg/mL above baseline

    Gastrinoma cells paradoxically release gastrin in response to secretin, so a rise of more than 120 pg/mL above baseline is the accepted diagnostic criterion in a patient with hypergastrinaemia and a low gastric pH. Normal antral G cells are suppressed by secretin, so a fall is the expected physiological response and argues against gastrinoma. Chromogranin A is a non-specific neuroendocrine marker and is also raised by PPI use. A meal-stimulated rise is characteristic of G-cell hyperplasia or retained antrum, not gastrinoma.

    Reference: NCCN Neuroendocrine and Adrenal Tumors Guidelines; Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed.

  6. Question 6 · Inflammatory Bowel Disease

    A 35-year-old man from a tuberculosis-endemic country has 4 months of abdominal pain, fever, night sweats and weight loss. Colonoscopy shows ulceration of the ileocaecal region with a patulous, gaping ileocaecal valve, and the ulcers are transversely oriented. Which additional finding would most strongly support intestinal tuberculosis rather than Crohn's disease?

    1. ALongitudinal serpiginous ulcers with cobblestoning
    2. BA perianal fistula
    3. CRectal sparing with skip lesions
    4. DConfluent caseating granulomas larger than 400 micrometres located submucosally
    Show answer and explanation

    Correct answer: D. Confluent caseating granulomas larger than 400 micrometres located submucosally

    Large, confluent, caseating granulomas, particularly when submucosal and accompanied by acid-fast bacilli or a positive tissue PCR or culture, are the most specific histological discriminator for intestinal tuberculosis; Crohn's granulomas are small, sparse, non-caseating and mucosal. Transverse ulcers, a patulous ileocaecal valve and a short segment of involvement also favour tuberculosis, whereas longitudinal ulcers, cobblestoning, skip lesions and perianal disease favour Crohn's. Making this distinction is critical because anti-TNF therapy given for misdiagnosed tuberculosis can cause fatal dissemination; where doubt persists, a therapeutic trial of antituberculous therapy with reassessment at 8-12 weeks is standard.

    Reference: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th edition (2021); Asia Pacific Consensus on Crohn's disease versus intestinal tuberculosis (Journal of Gastroenterology and Hepatology, 2018)

  7. Question 7 · Small and Large Intestine Disorders (non-IBD)

    A 55-year-old woman undergoes appendicectomy for presumed appendicitis. Histology reports a low-grade appendiceal mucinous neoplasm with acellular mucin confined within the appendiceal wall, an intact serosa, and a clear resection margin at the base. There was no free mucin in the peritoneal cavity at operation. What is the most appropriate management?

    1. ACompletion right hemicolectomy
    2. BAdjuvant systemic chemotherapy with oxaliplatin and capecitabine
    3. CImmediate cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    4. DSurveillance, as the risk of peritoneal recurrence is very low with disease confined to the appendix and negative margins
    Show answer and explanation

    Correct answer: D. Surveillance, as the risk of peritoneal recurrence is very low with disease confined to the appendix and negative margins

    A low-grade appendiceal mucinous neoplasm confined to the appendix with acellular mucin, an intact serosa and negative margins has a very low risk of peritoneal dissemination, and appendicectomy alone with clinical and imaging surveillance is sufficient. Right hemicolectomy is indicated for appendiceal adenocarcinoma or positive base margins, not for confined LAMN, because lymph node spread is negligible. Cytoreduction with HIPEC and systemic chemotherapy are treatments for established peritoneal disease such as pseudomyxoma peritonei, which is absent here.

    Reference: PSOGI International Consensus on the Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Appendiceal Mucinous Neoplasms (Carr et al., Am J Surg Pathol, 2016)

  8. Question 8 · Chronic Liver Disease, Cirrhosis and Portal Hypertension

    A 58-year-old man with cirrhosis and tense ascites has a large umbilical hernia. The overlying skin has ulcerated and clear ascitic fluid is now leaking continuously from the site. What is the most appropriate management?

    1. AUrgent surgical repair with simultaneous control of ascites, intravenous antibiotics and albumin support
    2. BApply a pressure dressing and manage him conservatively as an outpatient
    3. CPlan elective repair in six months once he is nutritionally optimised
    4. DLarge-volume paracentesis alone and discharge with diuretics
    Show answer and explanation

    Correct answer: A. Urgent surgical repair with simultaneous control of ascites, intravenous antibiotics and albumin support

    Spontaneous rupture of an umbilical hernia with ascitic leak (Flood syndrome) carries a high risk of bacterial peritonitis, hypovolaemia and death, so it demands urgent surgical repair together with aggressive control of ascites (diuretics, paracentesis, and TIPS where appropriate), antibiotics and albumin, since uncontrolled ascites is what drives recurrence and wound failure. Conservative dressings do not stop the leak or the infectious risk, and deferring repair for months exposes the patient to that risk throughout. Paracentesis alone temporarily decompresses the abdomen but leaves the fascial defect and ulcerated skin unaddressed.

    Reference: AASLD Practice Guidance on ascites and its complications (Biggins et al., Hepatology 2021); Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th edition, 2021

  9. Question 9 · Patient Safety, Professionalism, Ethics and Evidence-Based Practice

    Three patients who underwent ERCP within a two-week period develop bacteraemia with an identical multidrug-resistant Klebsiella pneumoniae isolate. Which is the most appropriate immediate infection control response?

    1. AContinue the ERCP list unchanged while awaiting further cases to confirm a trend
    2. BQuarantine the implicated duodenoscopes, culture them and review reprocessing records, notify infection control, and undertake look-back to identify other exposed patients
    3. CSwitch all patients to empirical carbapenem prophylaxis before ERCP
    4. DIncrease the concentration of the high-level disinfectant beyond manufacturer specification
    Show answer and explanation

    Correct answer: B. Quarantine the implicated duodenoscopes, culture them and review reprocessing records, notify infection control, and undertake look-back to identify other exposed patients

    A cluster of genetically indistinguishable resistant organisms after ERCP is a presumptive duodenoscope-associated outbreak requiring immediate device quarantine and culture, review of reprocessing practice, notification of infection prevention and control, and a patient look-back with disclosure. Waiting for more cases exposes further patients to harm. Blanket carbapenem prophylaxis treats the symptom rather than the transmission source and drives resistance, and exceeding manufacturer-specified disinfectant concentrations is unvalidated, damages the device and is not a recognised control.

    Reference: US FDA safety communications on duodenoscope-associated infections and ESGE-ESGENA Guideline on reprocessing flexible endoscopes, 2018

  10. Question 10 · Oesophageal Diseases

    During balloon dilation of a benign distal oesophageal stricture, a 10 mm full-thickness defect is recognised immediately. The patient is haemodynamically stable, apyrexial and has no pleural collection on urgent CT, which shows only a small volume of mediastinal air. Which management strategy is most appropriate?

    1. AImmediate thoracotomy with primary surgical repair in all cases
    2. BContinue the procedure and arrange an outpatient contrast study in 1 week
    3. CInsert a large-bore nasogastric tube across the defect and start oral feeding after 24 hours
    4. DImmediate endoscopic closure with clips (through-the-scope or over-the-scope) or a covered stent, plus nil by mouth, broad-spectrum antibiotics and close observation
    Show answer and explanation

    Correct answer: D. Immediate endoscopic closure with clips (through-the-scope or over-the-scope) or a covered stent, plus nil by mouth, broad-spectrum antibiotics and close observation

    An iatrogenic perforation recognised immediately in a stable patient without established mediastinal or pleural contamination is ideally managed endoscopically, using clips for small defects or a fully covered self-expanding metal stent for larger ones, combined with nil by mouth, broad-spectrum antibiotics, nutritional support and drainage of any collection. Surgery is reserved for large defects, failed endoscopic closure, established sepsis or clinical deterioration. Ignoring the defect or feeding the patient early would allow mediastinitis to develop.

    Reference: ESGE Position Statement: Diagnosis and management of iatrogenic endoscopic perforations, Endoscopy 2020; WSES position paper 2019

  11. Question 11 · Biliary Tract and Gallbladder Disease

    A 46-year-old shepherd with a large hepatic hydatid cyst develops jaundice, fever and biliary colic. Imaging shows cyst rupture into the biliary tree with daughter cysts and membranes in a dilated common bile duct. Which management is most appropriate?

    1. AAlbendazole alone, since endoscopic intervention risks anaphylaxis and is contraindicated
    2. BPercutaneous PAIR of the cyst as the sole treatment
    3. CERCP with sphincterotomy and extraction of daughter cysts and membranes, with albendazole cover and definitive management of the residual cyst
    4. DEmergency liver resection in all cases of cystobiliary fistula
    Show answer and explanation

    Correct answer: C. ERCP with sphincterotomy and extraction of daughter cysts and membranes, with albendazole cover and definitive management of the residual cyst

    Rupture of a hydatid cyst into the biliary tree causes obstruction and cholangitis, and ERCP with sphincterotomy and clearance of membranes and daughter cysts is both effective and the standard first response, with albendazole and subsequent surgical or percutaneous treatment of the residual cavity. PAIR is contraindicated when there is communication with the biliary tree because scolicidal agents can cause sclerosing cholangitis, albendazole alone will not relieve mechanical obstruction, and emergency resection is not required for most cystobiliary fistulae.

    Reference: WHO Informal Working Group on Echinococcosis: expert consensus on cystic echinococcosis (Acta Tropica, 2010); Sleisenger and Fordtran's, 11th edition (2021)

  12. Question 12 · Gastric and Duodenal Diseases and Helicobacter pylori

    A 51-year-old man failed bismuth quadruple therapy and then failed a course of PPI, amoxicillin and clarithromycin. He is not penicillin-allergic, susceptibility testing is unavailable, and local fluoroquinolone resistance is reported around 10%. Which salvage regimen is most appropriate?

    1. APPI, amoxicillin and levofloxacin for 14 days
    2. BRepeat the same bismuth quadruple regimen for a further 14 days
    3. CPPI, amoxicillin and metronidazole for 7 days
    4. DPPI and clarithromycin with rifabutin for 14 days
    Show answer and explanation

    Correct answer: A. PPI, amoxicillin and levofloxacin for 14 days

    After failure of both bismuth quadruple and a clarithromycin-containing regimen, a levofloxacin-based triple (or quadruple) regimen for 14 days is a guideline-endorsed salvage option where quinolone resistance is low. Simply repeating an identical failed regimen is discouraged, and clarithromycin should never be re-used after failure because of induced resistance. Rifabutin-containing therapy is generally reserved for later-line use to preserve it and to limit mycobacterial resistance and myelotoxicity risk; a 7-day metronidazole triple is inadequate.

    Reference: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (Am J Gastroenterol, 2024); Maastricht VI/Florence Consensus (Gut, 2022)

Gastroenterology reference books and guidelines

Every question in this bank names the textbook or guideline its answer rests on. These are the sources our Gastroenterology questions cite most often - the reading list to revise from alongside the bank.

Textbooks

4
  1. 1

    Sleisenger and Fordtran's Gastrointestinal and Liver Disease

    11th edition2021
  2. 2

    BSG Guidelines for the Investigation of Chronic Diarrhoea in Adults

    3rd edition
  3. 3

    Users' Guides to the Medical Literature

    3rd edition
  4. 4

    SCFHS Essentials of Patient Safety

Guidelines and standards

10
  1. 1

    Baveno VII Consensus Workshop, J Hepatol

    2022
  2. 2

    Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol

    2022
  3. 3

    ACG Clinical Guideline: Treatment of Helicobacter pylori Infection (Am J Gastroenterol)

    2024
  4. 4

    Maastricht VI/Florence Consensus (Gut)

    2022
  5. 5

    WHO Informal Working Group on Echinococcosis: Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis (Acta Tropica)

    2010
  6. 6

    WHO Patient Safety Curriculum Guide

    2011
  7. 7

    BSG Barrett's guideline

    2023
  8. 8

    ESGE Position Statement on artificial intelligence in gastrointestinal endoscopy, Endoscopy

    2022
  9. 9

    AGA Institute Guideline on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant IBS (Gastroenterology)

    2019
  10. 10

    ESGE Guideline: Tissue sampling with EUS, Endoscopy ( technical review)

    2021

Where your regulator publishes a reading list, use the editions it names. Exam questions are not taken from any one book.

Last reviewed September 2026

About these questions: every question is original, researched by Neelim's exam research team, written to the published blueprint, with a rationale and a reference. No recalled or leaked exam content is used. How we write our questions.

Frequently asked questions

Are these real Gastroenterology exam questions?
No. Every item is original, researched by Neelim's exam research team against the exam blueprint published by the health authorities. Real, recalled or leaked exam content breaches the testing bodies' rules and can lead to a permanent exam ban - we do not sell it, and neither should anyone else.
How many questions are in the Gastroenterology bank?
Every bank starts at 3 full-length papers of roughly 170 questions each (the DHA exam itself is 150 questions), and you can add papers up to 6, including a bonus paper of our hardest questions. The papers do not overlap, so every question is new, and together they cover every sub-topic in the published blueprint.
What is the pass mark for the DHA Gastroenterology exam?
65%. DHA publishes the pass score for each exam, and 65% is the figure for Specialist Gastroenterology (GES5171) in the DHA CBT Guideline, Sep 2026. The result is posted to your Sheryan account as Pass or Fail only - your score is not shared. Elsewhere in the GCC: SCFHS 65%, QCHP 65%.
How many questions are in the DHA Gastroenterology exam, and how long is it?
150 multiple-choice questions in 3 hours, and the time includes registration and the introduction. It is a computer-based test delivered by Prometric at test centres in the UAE and abroad.
How much does the DHA Gastroenterology exam cost?
USD 280 (about AED 1,030) per attempt, paid again for every re-sit. DHA also charges a flat AED 200 credentialing fee through Sheryan.
How many attempts do I get?
In the UAE, three in total across DHA, DOH, MOHAP and SHA, not three each, under clause 1.5.4 of the Unified PQR (April 2025). Clause 1.5.5 allows one further attempt with a different authority, except on the Consultant route. Elsewhere in the GCC: SCFHS up to 4 a year, QCHP 5 per scope, OMSB no set maximum, Kuwait MOH 3, 6 weeks apart.
Which GCC regulators license the Gastroenterology title?
DHA sets a written exam (Specialist Gastroenterology (GES5171)); SCFHS sets a written exam (Saudi Classification Examination - Gastroenterology); QCHP sets a written exam (Specialist Gastroenterology). DOH licenses the title without a published written exam (credential review, interview or an unpublished assessment). OMSB, Kuwait MOH publish no exam for this title. This bank prepares you for the written exams, and its content is the core knowledge any interview or assessment for the title draws on.
How do I receive it?
As PDF files. Card checkout is being set up, so for now you request it from this page and we send it to you directly, usually the same day.

Still unsure whether you even need this exam?

Your route depends on your profession, your licence title and the authority. We have guided over 1,000 professionals through GCC licensing - tell us your situation and we will confirm exactly what you need to sit.